作者
Davide Grassi, Livia Ferri, Giovambattista Desideri, Paolo Di Giosia, Paola Cheli, Rita Del Pinto, Giuliana Properzi, Claudio Ferri
发表日期
2013/4/1
来源
Current pharmaceutical design
卷号
19
期号
13
页码范围
2432-2438
出版商
Bentham Science Publishers
简介
Hyperuricemia is commonly associated with traditional risk factors such as dysglicemia, dyslipidemia, central obesity and abnormal blood pressure, i.e. the metabolic syndrome. Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality. In this regard, different studies also evaluated the possible role of xanthine inhibitors in inducing blood pressure reduction, increment in flow-mediated dilation, and improved cardiovascular prognosis in various patient settings. The vast majority of these studies have been conducted with either allopurinol or its active metabolite oxypurinol, i.e. two purine-like non-selective inhibitors of xanthine oxidase. More recently, the role of uric acid as a risk factor for cardiovascular disease and the possible protective role exerted by reduction of …
引用总数
20132014201520162017201820192020202120222023202415333336272231272821238
学术搜索中的文章
D Grassi, L Ferri, G Desideri, P Di Giosia, P Cheli… - Current pharmaceutical design, 2013